Singletary Gretchen E, Saunders Ashley B, Saunders W Brian, Suchodolski Jan S, Steiner Jörg M, Fosgate Geoffery T, Hartsfield Sandee M
Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843-4474, USA.
Vet Anaesth Analg. 2010 Jul;37(4):342-6. doi: 10.1111/j.1467-2995.2010.00540.x.
To evaluate the effect of medetomidine-butorphanol sedation on serum cardiac troponin I (cTnI) concentration, a marker of myocardial ischemia and injury, in healthy dogs undergoing pre-surgical radiographs for orthopedic procedures.
Prospective clinical study.
Twenty client-owned dogs with no history of cardiac disease.
Dogs were evaluated for pre-existing cardiac disease with electrocardiogram (ECG), noninvasive blood pressure and echocardiogram. Sedation was achieved using a combination of medetomidine (10 microg kg(-1)) and butorphanol (0.2 mg kg(-1)) intravenously. Blood pressure, heart rate and ECG were serially recorded throughout the duration of sedation. Serum cTnI concentration was measured at baseline and 6, 18, and 24-hours post-sedation.
Following administration of medetomidine and butorphanol, all dogs were adequately sedated for radiographs and had a decreased heart rate and increased diastolic blood pressure. Arrhythmias associated with increased parasympathetic tone occurred, including a sinus arrhythmia further characterized as a sinus bigeminy in 17 of the dogs. Serum cTnI was undetectable at all time points in all but three dogs. Two of the three dogs had a detectable concentration of cTnI at all time points measured, including prior to sedation. Only one of the two dogs had a cTnI concentration above the normal reference interval. The dogs that exhibited detectable cTnI had no significant difference in signalment, heart rate, blood pressure, or lactate concentration as compared to those with undetectable cTnI.
Sedation with medetomidine and butorphanol had predictable cardiovascular effects including bradycardia, an increase in arterial blood pressure, and arrhythmias in apparently healthy dogs requiring radiographs for orthopedic injuries, but did not induce significant increases in serum cTnI concentration following the drug doses used in this study.
评估美托咪定 - 布托啡诺镇静对接受骨科手术术前X光检查的健康犬血清心肌肌钙蛋白I（cTnI）浓度的影响，cTnI是心肌缺血和损伤的标志物。
前瞻性临床研究。
20只无心脏病史的客户拥有的犬。
通过心电图（ECG）、无创血压和超声心动图对犬进行潜在心脏病评估。静脉注射美托咪定（10微克/千克）和布托啡诺（0.2毫克/千克）联合用药实现镇静。在镇静期间连续记录血压、心率和ECG。在基线以及镇静后6、18和24小时测量血清cTnI浓度。
给予美托咪定和布托啡诺后，所有犬均被充分镇静以进行X光检查，心率降低，舒张压升高。出现了与副交感神经张力增加相关的心律失常，包括17只犬出现窦性心律失常，进一步表现为窦性二联律。除三只犬外，所有犬在所有时间点血清cTnI均未检测到。三只犬中的两只在所有测量时间点，包括镇静前，cTnI浓度均可检测到。这两只犬中只有一只的cTnI浓度高于正常参考区间。与cTnI未检测到的犬相比，cTnI可检测到的犬在品种、心率、血压或乳酸浓度方面无显著差异。
美托咪定和布托啡诺镇静对明显健康、因骨科损伤需要进行X光检查的犬具有可预测的心血管效应，包括心动过缓、动脉血压升高和心律失常，但在本研究使用的药物剂量后，并未导致血清cTnI浓度显著升高。
